Clinical Trial Update: Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating AZD4547 in combination with Fulvestrant versus Fulvestrant alone in estrogen receptor-positive breast cancer has completed, with sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AZD4547
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-11